Accessibility Menu
Kaleido Biosciences logo

Kaleido Biosciences(OTC) KLDO

Market Cap$4.30KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2019)-100%
5 Year-100%
1 Year+0%
1 Month+9,900%
$0.00
+0.00%
+0.00Today
Kaleido Biosciences last closing stock price
MetricPriceDate
Last closeUSD 0.002026-07-31
Kaleido Biosciences stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0%USD 0.002026-07-22
1 month+9,900%USD 0.002026-07-01
3 month+0%USD 0.002026-04-30
Year to date+0%USD 0.002025-12-30
1 year+0%USD 0.002025-07-31
3 year+0%USD 0.002023-08-01
5 year-100%USD 5.432021-07-30
Since inception-100%USD 14.232019-02-28

Kaleido Biosciences Financials at a Glance

Market Cap

$4.30KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$1.10M

Net Income (TTM)

-$91.95M

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

3365.45 (High)

Price

$0.00

Volume

700

Open

$0.00

Previous Close

$0.00

Daily Range

$0.00 - $0.00

52-Week Range

$0.00 - $0.35

Estimated Earnings Date

Aug 12, 2026

KLDO News

MandA Deal

All the 2020 Pre-JPM News Healthcare Investors Need to Know

Brian Orelli, PhDJan 11, 2020
493 gut microbiome

Will the Gut Microbiome Change Medicine? Wall Street Isn't Convinced.

Maxx ChatskoSep 17, 2019

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Kaleido Biosciences

Kaleido Biosciences, Inc. is a clinical-stage healthcare firm focused on developing microbiome metabolic therapies. The company is advancing a pipeline of drug candidates targeting various conditions, including urea cycle disorders and ulcerative colitis.

Products and Services
  • KB195 for urea cycle disorders
  • KB295 targeting ulcerative colitis
  • KB174 aimed at hepatic encephalopathy
Growth Outlook
  • Strategic collaborations with leading institutions enhance research capabilities
  • Focus on significant therapeutic areas like immuno-oncology and chronic kidney disease
  • Potential market expansion as microbiome therapies gain traction
Financial Highlights
  • Recent quarterly revenue of 492,000, showing growth potential
  • Cash and cash equivalents of 38.47 million, providing operational runway
  • Current ratio of 1.43 indicates solid short-term financial health
Kaleido Biosciences is positioned in the biotechnology sector, with a focus on innovative therapies that leverage the microbiome. The company has established a diverse pipeline, which includes drug candidates that address critical health issues. Collaborations with prominent research institutions are expected to bolster its development efforts and enhance its market presence. Financially, the company reported a recent quarterly revenue of 492,000, reflecting its ongoing efforts to commercialize its therapies. With cash and cash equivalents totaling 38.47 million, Kaleido has a solid foundation to support its research and development activities. The current ratio of 1.43 suggests that the company is well-equipped to meet its short-term obligations, which is a positive indicator for potential investors. Overall, Kaleido Biosciences presents an intriguing opportunity in the biotechnology space, particularly for those interested in the evolving field of microbiome therapies. The company's strategic focus on significant health challenges, combined with its financial positioning, may appeal to investors looking for growth in innovative healthcare solutions.
AI Generated • Jul 28, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

76

CEO

Daniel L. Menichella, MBA

Website

www.kaleido.com

Headquarters

Lexington, MA 02421, US

KLDO Financials

Key Financial Metrics (TTM)

Gross Margin

-113.59%

Operating Margin

-7940.85%

Net Income Margin

-8178.26%

Return on Equity

-580.57%

Return on Capital

-271.41%

Return on Assets

-180.08%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$4.30KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

42.62M

Volume

700

Avg. Volume

1.46K

Financials (TTM)

Gross Profit

$1.10M

Operating Income

-$87.67M

EBITDA

-$85.09M

Operating Cash Flow

-$77.09M

Capital Expenditure

-$1.13M

Free Cash Flow

-$78.22M

Cash & ST Invst.

$38.47M

Total Debt

$21.69M

Kaleido Biosciences Performance Analysis

Kaleido Biosciences annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20212021-12-31USD 1,104,000N/A
Kaleido Biosciences sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12021-03-3122.2%
Q22021-06-30-29.0%
Q32021-09-30-50.7%
Q42021-12-31373.1%
Kaleido Biosciences annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20212021-12-31USD -2.16N/A
Kaleido Biosciences sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12021-03-31-11.1%
Q22021-06-303.3%
Q32021-09-308.6%
Q42021-12-3199.9%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Currently no data to display.

Quarterly Performance

Name
Q4 2021YOY CHG

Revenue

$492.00K

+102.5%

Gross Profit

$492.00K

+102.5%

Gross Margin

100.00%

N/A

Market Cap

$4.30KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$56.58

N/A

Employees

76

N/A

Net Income

-$21.12M

-8.6%

EBITDA

-$18.95M

-1.2%

Quarterly Fundamentals

Name
Q4 2021YOY CHG

Total Cash

$38.47M

-16.8%

Total Debt

$21.69M

+3.3%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$5.55M

-69.8%

Short Term Debt

$16.14M

+512.9%

Return on Assets

-1.80%

N/A

Return on Invested Capital

-4.29%

N/A

Free Cash Flow

-$17.60M

-47.1%

Operating Cash Flow

-$17.16M

-51.9%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
BXRXQBaudax Bio, Inc.
$0.00+0.00%
IVBTInnovation1 Biotech Inc.
$0.00+0.00%
XENOXeno Transplants Corporation
$0.00+0.00%
TNGNQTengion, Inc.
$0.00+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
NVDANvidia
$200.75+0.03%
AAPLApple
$308.91-0.07%
AMZNAmazon
$271.58+0.15%
INTCIntel
$90.20-0.01%

Questions About KLDO

What is the current price of Kaleido Biosciences?

Kaleido Biosciences is trading at $0.00 per share.

What is the 52-week range for Kaleido Biosciences?

Over the past 52 weeks, Kaleido Biosciences has traded between $0.00 and $0.35.

How much debt does Kaleido Biosciences have?

As of the most recent reporting period, Kaleido Biosciences reported total debt of $21.69M.

How much cash does Kaleido Biosciences have on hand?

Kaleido Biosciences reported $38.47M in cash and cash equivalents in its most recent financial results.

What is Kaleido Biosciences’s dividend yield?

Kaleido Biosciences does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services